UNAIDS. Global HIV and AIDS statistics - fact sheet;2022.

World Health Organization. HIV drug resistance report 2019. Geneva:World Health Organization. 2019.

Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesa tahun 2019. Jakarta : Kementerian Kesehatan Republik Indonesia; 2020. Indonesian.

Kusumaningrum A, Ibrahim F, Yunihastuti E, Bela B. HIV drug resistance after failure of 6 month first-line therapy in a hospital: a case series. Acta Med Indones 2019;51:253–7.

Beyrer C, Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N Engl J Med 2017;377:1605–7. doi: 10.1056/ NEJMp1710608.

Zhang Y, Ma L. Application of high-throughput sequencing technology in HIV drug resistance detection. Biosaf Heal 2021;3:276–80. doi: 10.1016/j.bsheal.2021.06.002.

World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021.

World Health Organization. HIV drug resistance report 2021. Geneva: World Health Organization; 2021.

Zuo Z, Liang S, Sun X, et al. Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight province of China. PLoS ONE 2016;11:1-13. doi: 10.1371/journal.pone. 0166661.

Maruapula D, MacLeod I, Essex M, et al. Use of a mutation specific genotyping method to asses for HIV subtype C infected patients in Bostwana. AAS Open Res 2021;7:1-20. doi: 10.12688/ aasopenres.13107.2.

Li Q, Yu F, Song C, et al. A concentration method for HIV drug resistance testing in low-level viremia samples. Biomed Res Int 2022;2022: 2100254. doi: 10.1155/2022/2100254.

Khairunisa SQ, Megasari NLA, Indriati DW, et al. Identification of HIV-1 subtypes and drug resistance mutations among HIV-1-infected individuals residing in Pontianak, Indonesia. Germs 2020;10:174-183. doi: 10.18683/germs. 2020.1203.

Hutapea H, Fitriana E, Natalia I, Wahyuni T, Adiningsih S, Widiyanti M. Description of mutation cases related to antitroviral resistance in people with HIV-AIDS (PLWHA) in three districts/cities in Papua Province. Papua Litbangkes Cent 2018;1–8.

Wallis CL, Aga E, Ribaudo H,et al. A5230 team. Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis 2014;59:706-15. doi: 10.1093/cid/ ciu314.

Al-Omairi O, Elgalib A, Al Kindi H. HIV drug resistance among patients failing therapy at a tertiary centre in Oman: a case record review. Oman Med J 2019; 34:491-5. doi: 10.5001/omj. 2019.91.

Scriven YA, Mulinge MM, Saleri N, et al. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study. Med (United States) 2021;100: E27460. doi: 10.1097/MD.0000000000027460.

Seu L, Mulenga L, Mpanji S, Sikazwe L, Guffey M, Chi B. Characterization of HIV drug resistance mutations among patients failing first line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia. J Med Virol 2015;87: 1149-57. doi :

Mulisa D, Tolossa T, Bayisa L, Abera T, Wakuma B. First-line virologic-based ART treatment failure and associated factors among adult HIV Positives in Southwest Shoa, Central Ethiopia. J Int Assoc Provid AIDS Care 2022;21: 23259582221111080. doi: 10.1177/ 23259582221111080.

Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China national free antiretroviral treatment program. Ann Intern Med 2009;151:241-51, W-52. doi: 10.7326/0003-4819-151-4-200908180-00006.

World Health Organization. WHO manual for HIV drug resistance testing using dried blood spot specimens. Geneva: World Health Organization; 2012.

Hutapea HML, Kridaningsih TN, Prasetyo KH, Antwi MB. Viral load as a risk factor of reverse transcriptase inhibitor drug resistance mutation in antiretroviral-treated people living with HIV/AIDS. Univ Med 2021;40:243–53. doi: 10.18051/UnivMed.2021.v40.243-253.